

**The 16th KICancer/StratCan Retreat
September 25-26 2017
Program**

Monday, September 25

- 08.30 Departure by bus from the City Terminal, Klarabergs-
viadukten, Stockholm
- 09.30 Arrival conference center. Djurönäset, Coffee & tea
- 09.50 Meeting opens & Welcome Remarks
- 10.00 – 12.35 Chairs: Kamlia Czene and Rune Toftgård
Scientific presentations
- 10.00 – 10.40 **Invited speaker**
Ron De Pinho, MD Anderson, Houston
Targeting Cancer-Specific Vulnerabilities
- 10.45 – 11.00 **Invited speaker**
Stephan Mielke, R&E Director Theme Cancer & CAST,
Karolinska University Hospital
Harnessing Alloimmunity for Cancer Treatment
- 11.03 – 11.15 **Charlotte Rolny**, Department of Oncology-Pathology, CCK
*Translational control of the macrophage phenotype during
cancer growth*
- 11.18 – 11.33 **Invited speaker**
Katy Rezvani, MD Anderson, Houston
*Off-the-shelf CAR-engineered cord blood-derived NK cells
for the treatment of cancer- the first-in-human trial*
- 11.36 – 11.51 **Invited speaker**
Gordon Mills, MD Anderson, Houston
Delivering on the promise of personalized medicine
- 11.54 - 12.09 **Invited speaker**
Martin Bergö, BIONUT, Huddinge
*Metabolic rewiring by antioxidants stimulates lung
cancer metastasis in mice*

- 12.12 – 12.27 **Invited speaker**
Rolf Lewensohn, Department of Oncology Pathology
Malignant pleural effusions from lung cancer patients offer a source of primary cells for biomarker discovery and therapeutic testing
- 12.30 – 12.40 **Photo session**
- 12.45 – 13.45 LUNCH
- 13.45 - 14.15 Chairs: Charlotte Rolny and Arne Östman
Scientific presentations
Invited speaker
Seishi Ogawa, Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University
A novel mechanism of cancer immune evasion via the disruption of PD-L1 3'-UTR
- 14.20 – 14.35 **Invited speaker**
Hanna Eriksson & Johan Hansson, Dept of Oncology and Pathology
Outcome data and translational studies of melanoma
- 14.38 – 14.53 **Invited speaker**
Yvonne Brandberg, Dept of Oncology and Pathology
Care science in the context of translational cancer research
- 14.56 – 15.08 **Linda S. Lindström**, Department of Biosciences and Nutrition
Increased long-term risk of fatal breast cancer in patients with high intra-tumor heterogeneity of the estrogen receptor
- 15.10 – 15.40 COFFEE/TEA. CHECK IN
- 15.40 - 15.55 Chair: Tina Dalianis and Ingemar Ernberg
Invited speaker
Anders Gustafsson, Dean of Research, KI
The Board of Research, Cancer Research and Education

- Invited speaker**
- 16.00 – 16.20 **Harald Blegen**, Theme cancer leader.
Highlights from the current Theme Cancer process
- 16.25 *Introduction to Break Out Sessions*
- 16.35 - 17.50 *Break Out Sessions*
- 16.35 – 17.50 **Break out session NUMBER ONE (I) in ROOM A House 1**
Methods and treatment development
Chairs: Kristina Viktorsson and Lars Holmgren
- Scientific Presentations**
- 16.35 - 16.47 **Twana Alkasalias**, MTC
Live cell Imaging-High throughput system to study cells behavior, interaction and heterogeneity.
- 16.50 - 17.02 **Raoul Kuiper**, FENO at Dept of Lab Medicine, Huddinge
Morphologic phenotype analysis-analyzing tissue in context of the model organism.
- 17.05 - 17.17 **Sean Rudd**, Science For Life Laboratory, Division of Translational Medicine and Chemical Biology, MBB
SAMHD1 is a barrier to antimetabolite-based cancer therapies
- 17.20 – 17.32 **Mats Ferm**, KI Innovations AB, StratCan and Department of Oncology & Pathology
Can your discovery become the next breakthrough in cancer therapy or diagnosis? Transform your discovery into benefits for the patients - by doing business

- 16.35 – 17.50 **Break out session number TWO (II) in
ROOM A House 2**
Basic research
Chairs: Gayathri Chandrasekar-Janebjer & Boris
Zhivotovsky
- 16.35 - 16.47 **Idha Kurtsdotter**, Ludwig Institute for Cancer Research and
CMB
*SOX5/6/21 prevent oncogene-driven transformation of brain
stem cells*
- 16.50 - 17.02 **Franziska M. Zickgraf**, German Cancer Research Center
(DKFZ), Heidelberg, Germany
*SSEA1⁺ cells mark a tumor-initiating population in serous
ovarian cancer*
- 17.05 - 17.17 **Olle Lindberg**, Institute of Environmental Medicine
(IMM), Toxicology Unit
*Post-translational modifications of Epidermal growth Factor
receptor variant III (EGFRvIII) regulate tumor cell behavior
in model for GBM*
- 17.20 – 17.32 **Shuijie Li**, Ludwig Institute for Cancer Research and MTC,
*VHL regulates mitochondrial mass in a hydroxylation
dependent manner, providing a novel oxygen sensing
pathway that is defective in VHL type-2C disease*
- 17.35 – 17.47 **Vitaliy Kaminsky**, Institute of Environmental Medicine,
Division of Toxicology, Karolinska Institutet
*Suppressed translation as a mechanism of initiation of
apoptosis in autophagy-deficient NSCLC cells under nutrient
limitation*

- 11.18 – 11.30 **Marios Dimitriou**, Center for Hematology and Regenerative Medicine, KI & Department of Medicine, Karolinska University Hospital Huddinge
Molecular probing of distinct stem and progenitor populations improves post-allogeneic transplantation prediction of relapses in MDS patients
- 11.35 - 12.30 LUNCH
- 12.30 – 13.55 Chairs: Marie Arsenian-Henriksson and Claes Karlsson
Scientific presentations
- 12.30 – 13.10 **Invited speaker**
Michael Davies, MD Anderson, Houston
The role of the PI3K-AKT pathway in CNS metastasis and therapeutic resistance in melanoma
- 13.15 - 13.27 **Johan Lindberg**, MEB
Liquid biopsies in metastatic prostate cancer
- 13.30 - 13.42 **Isabelle Westerlund**, CMB, Ludwig Institute for Cancer Research, MTC, Department of Women's and Children's Health, Karolinska Institutet
Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2 α to tumor suppression
- 13.45 – 13.57 **Richard Rosenquist Brandell**, Dept of Molecular Medicine and Surgery
Genomic Medicine Sweden initiative - a coordinated national integration of precision medicine in Swedish Healthcare
- 14.00 - 14.30 COFFEE
- 14.30 - 15.15 **Scientific presentations**
- 14.30 - 14.42 Chairs: Jonas Fuxe and Mikael Karlsson
Mikael Eriksson, MEB
Clinical model for identifying the short-term risk of breast cancer

- 14.45 – 14.57 **Noriyuki Sumida, MTC**
Oncogenic enhancers dynamically associated with MYC influence its post-transcriptional regulation by mediating gene-nuclear pore interactions
- 15.00 – 15.12 **Nicola Crosetto, Science for Life Laboratory, MBB**
Targeting Genomic Fragility in Cancer
- 15.15 **Conclusions; Poster prizes**
- 16.00 Bus departure
- 17.00 appr Arrival Stockholm City Terminal